The Astrocyte-Derived α7 Nicotinic Receptor Antagonist Kynurenic Acid Controls Extracellular Glutamate Levels in the Prefrontal Cortex
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The cognitive deficits seen in schizophrenia patients are likely related to abnormal glutamatergic and cholinergic neurotransmission in the prefrontal cortex. We hypothesized that these impairments may be secondary to increased levels of the astrocyte-derived metabolite kynurenic acid (KYNA), which inhibits α7 nicotinic acetylcholine receptors (α7AChR) and may thereby reduce glutamate release. Using in vivo microdialysis in unanesthetized rats, we show here that nanomolar concentrations of KYNA, infused directly or produced in situ from its bioprecursor kynurenine, significantly decrease extracellular glutamate levels in the prefrontal cortex. This effect was prevented by the systemic administration of galantamine (3 mg/kg) but not by donepezil (2 mg/kg), indicating that KYNA blocks the allosteric potentiating site of the α7AChR, which recognizes galantamine but not donepezil as an agonist. In separate rats, reduction of prefrontal KYNA formation by (S)-4-ethylsulfonyl benzoylalanine, a specific inhibitor of KYNA synthesis, caused a significant elevation in extracellular glutamate levels. Jointly, our results demonstrate that fluctuations in endogenous KYNA formation bidirectionally influence cortical glutamate concentrations. These findings suggest that selective attenuation of cerebral KYNA production, by increasing glutamatergic tone, might improve cognitive function in individuals with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., et al. (2003) · Nature · doi:10.1038/nature01339 · Cited by 3,228
Mammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724 · cited 3×
“…on postsynaptic, somatodendritic structures and on nonglutamatergic nerve endings (Csillik et al. 1998; Alkondon et al. 2000; Krenz et al. 2001; Albuquerque et al. 2009), so that it is conceivable that the inhibition of α7nAChRs receptors by KYNA reduces glutamate levels indirectly—either…”
Self-citationIncreased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Self-citationCognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations
Lewis, D. A., & Moghaddam, B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1372 · Cited by 404 · cited 2×
“…functions (i.e., attention, cognitive flexibility), are mediated by the prefrontal cortex (PFC; Kerns et al. 2008; Moghaddam and Homayoun 2008), and may be causally related to abnormal glutamatergic and cholinergic neurotransmission within the PFC (Sarter et al. 2005; Lewis and Moghaddam 2006).”
Couey, J. J., Meredith, R. M., Spijker, S., Poorthuis, R. B., Smit, A. B., Brussaard, A. B., & Mansvelder, H. D. (2007) · Neuron · doi:10.1016/j.neuron.2007.03.006 · Cited by 253 · cited 1×
“*p<0.05 vs. the baseline (one-way ANOVA) J Mol Neurosci Arco and Mora 2005, 2008; Biton et al. 2007; Couey et al. 2007).”
InfluentialAlkondon, M., Pereira, E. F. R., Eisenberg, H. M., & Albuquerque, E. X. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00066.2000 · Cited by 248 · cited 2×
“However, α7nAChRs are also situated on postsynaptic, somatodendritic structures and on nonglutamatergic nerve endings (Csillik et al. 1998; Alkondon et al. 2000; Krenz et al. 2001; Albuquerque et al. 2009), so that it is conceivable that the inhibition of α7nAChRs receptors by KYNA reduces glutamate levels indirectly—…”
Self-citationGioanni, Y., Rougeot, C., Clarke, P. B. S., Lepousé, C., Thierry, A. M., & Vidal, C. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00403.x · Cited by 191 · cited 1×
“Throughout the forebrain, this effect is presumably initiated mainly by the blockade of presynaptic α7nAChRs on glutamatergic nerve terminals (Gioanni et al. 1999; Marchi et al. 2002; Rousseau et al. 2005; Dickinson et al. 2008).”
Galantamine for the treatment of cognitive impairments in people with schizophrenia
Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050724 · Cited by 170
Del Arco, A., & Mora, F. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.04.011 · Cited by 163 · cited 2×
“*p<0.05 vs. the baseline (one-way ANOVA) J Mol Neurosci Arco and Mora 2005, 2008; Biton et al. 2007; Couey et al. 2007).”
InfluentialCortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
Sarter, M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi006 · Cited by 153 · cited 2×
“…functions (i.e., attention, cognitive flexibility), are mediated by the prefrontal cortex (PFC; Kerns et al. 2008; Moghaddam and Homayoun 2008), and may be causally related to abnormal glutamatergic and cholinergic neurotransmission within the PFC (Sarter et al. 2005; Lewis and Moghaddam 2006).”
Cited by
Verkhratsky, A., & Nedergaard, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00042.2016 · Cited by 1,678
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Self-citationNeuroinflammation and depression: A review
Troubat, R., Barone, P., Leman, S., Desmidt, T., Cressant, A., Atanasova, B., Brizard, B., El Hage, W., Surget, A., Belzung, C., et al. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14720 · Cited by 1,107
Neuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
“acetylcholine receptor (α7nAchR) [195], leading to decreased NMDAR function and reduced α7nAchR-mediated glutam-”
Astrocytes as secretory cells of the central nervous system: idiosyncrasies of vesicular secretion
Verkhratsky, A., Matteoli, M., Parpura, V., Mothet, J., & Zorec, R. (2016) · The EMBO Journal · doi:10.15252/embj.201592705 · Cited by 397
Tryptophan-kynurenine pathway is dysregulated in inflammation and immune activation
Zou, M.-H. (2015) · Frontiers in Bioscience · doi:10.2741/4363 · Cited by 361
Increased Levels of Kynurenine and Kynurenic Acid in the CSF of Patients With Schizophrenia
Linderholm, K. R., Skogh, E., Olsson, S. K., Dahl, M.-L., Holtze, M., Engberg, G., Samuelsson, M., & Erhardt, S. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq086 · Cited by 325
Kynurenine pathway in depression: a systematic review and meta-analysis
Ogyu, K., Kubo, K., Noda, Y., Iwata, Y., Tsugawa, S., Omura, Y., Wada, M., Tarumi, R., Plitman, E., Moriguchi, S., et al. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.023 · Cited by 301
Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., & Schwarcz, R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq112 · Cited by 253
Self-citationCortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in Schizophrenia
Wonodi, I., & Schwarcz, R. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq002 · Cited by 190
Self-citationLuo, J., Wang, T., Liang, S., Hu, X., Li, W., & Jin, F. (2014) · Science China Life Sciences · doi:10.1007/s11427-014-4615-4 · Cited by 187
Reduction of Brain Kynurenic Acid Improves Cognitive Function
Kozak, R., Campbell, B. M., Strick, C. A., Horner, W., Hoffmann, W. E., Kiss, T., Chapin, D. S., McGinnis, D., Abbott, A. L., Roberts, B. M., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1107-14.2014 · Cited by 180
“, 2009) or possibly may regulate glutamate and/or acetylcholine release through an interaction at the nicotinic 7 receptor (Hilmas et al., 2001; Rassoulpour et al., 2005; Lopes et al., 2007; Wu et al., 2010), although it is worth noting that direct changes in dopamine release after treatment with PF-04859989 were not…”
BackgroundKynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A., & Urbanska, E. M. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13768 · Cited by 142
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease
Fontana, I. C., Kumar, A., & Nordberg, A. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00792-4 · Cited by 86
Metadata
- Authors
- Wu, H.-Q., Pereira, E. F. R., Bruno, J. P., Pellicciari, R., Albuquerque, E. X., & Schwarcz, R.
- Venue
- Journal of Molecular Neuroscience
- Published
- 2009-08-19
- Volume
- 40
- Issue
- 1-2
- Pages
- 204-210
- ISSN
- 0895-8696 (ISSN-L)
- 1559-1166
- OpenAlex
- W2111909949
- Cited by
- 146
- References
- 10
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.